KLOW peptide: what is in it and does it work?

What is in KLOW?

KLOW contains GHK-Cu, BPC-157, TB-500 (thymosin beta-4), and KPV. Products sold as KLOW usually list GHK-Cu, BPC-157, TB-500, and KPV in one vial. The amounts and ratios differ from seller to seller, and research-chemical labels are not verified by any drug standard. PeptideAgent does not name or link sellers.

Also searched as: Klow peptide blend; KLOW blend; GHK-Cu, BPC-157, TB-500, and KPV blend.

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in KLOW?

KLOW is marketed as GLOW with an anti-inflammatory added. The claimed benefits are the GLOW claims (skin and collagen from GHK-Cu, tissue healing from BPC-157 and TB-500) plus calmer inflammation, especially in the gut and skin, from KPV.

KPV is the last three amino acids of alpha-melanocyte stimulating hormone. In two independent 2008 mouse studies, KPV given by mouth reduced chemically induced colitis, with lower inflammatory markers and faster recovery. Those two studies are the whole evidence base for the KPV part of the pitch. [1] [2] [3] [6]

Has KLOW been studied?

No published study has tested KLOW, or any mix of GHK-Cu, BPC-157, TB-500, and KPV, in humans or animals.

Every ingredient has the same gap on its own. There is no human trial of injected GHK-Cu. BPC-157 has preclinical work and three small uncontrolled pilot reports (knee pain, interstitial cystitis, IV safety). Full-length thymosin beta-4 has small phase 1 and phase 2 human trials (IV safety, eye drops for dry eye, topical gel for skin ulcers). None tested injected TB-500 for injury healing. KPV has no human trial for any use, and the mouse studies gave it by mouth, not by injection.

Adding a fourth peptide multiplies the unknowns rather than the evidence: stability in a shared vial, interactions between the peptides, and additive side effects have not been studied. [2] [4] [7] [8] [13] [14] [15]

What each ingredient has shown alone

• GHK-Cu (human observational evidence). Copper binding three amino acid peptide with decades of skin and wound data: lawful and well studied in skin cosmetics, unapproved and untested as an injection.
• BPC-157 (animal-only evidence). A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a shifting FDA compounding status.
• TB-500 (thymosin beta-4) (animal-only evidence). Copy or fragment of the repair protein thymosin beta-4: strong animal data, small human trials of the full protein, no trial of injected TB-500; WADA banned.
• KPV (animal-only evidence). Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; recommended for FDA's compounding list in July 2026, rule pending.

KLOW results and before and after claims

KLOW before and after claims rest on photos and testimonials, not measured outcomes. No study has measured skin, gut, joint, or recovery outcomes after injecting KLOW or any of its four peptides in people.

The closest measured human data are small topical GHK-Cu cosmetic studies, which used a cream rather than an injection. For KPV, the measured outcomes are colitis scores in mice.

A 2026 review of peptides marketed for recovery notes that placebo effects, amplified by social media, can explain much of what users report. Claimed KLOW benefits should be read as untested. [2] [3] [8]

What are the side effects of KLOW?

No study has recorded the side effects of KLOW. The injectable forms of all four ingredients lack systematic human safety data.

Reported and theoretical concerns include injection site pain and irritation, the untested possibility that growth-promoting peptides affect existing tumors, and, for KPV, a theoretical effect on the response to infection because it dampens inflammatory signaling. None of these has been studied in people.

Unregulated manufacturing adds risk. The BPC-157 systematic review warns that contamination and wrong content are possible in products made outside drug standards, and a four-peptide vial is harder to verify than a single peptide. [1] [5] [7] [8]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Is KLOW legal?

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For KLOW that is GHK-Cu: no lawful path. At least one ingredient cannot be lawfully compounded or prescribed, so no licensed pharmacy can lawfully make the mix.

• GHK-Cu regulatory timeline (Removed from Category 2 (Apr 2026))
• BPC-157 regulatory timeline (Under FDA review)
• TB-500 (thymosin beta-4) regulatory timeline (Under FDA review)
• KPV regulatory timeline (Under FDA review)

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [10]

WADA status

BPC-157, TB-500 (thymosin beta-4), and KPV are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does KLOW cost, and what can a provider lawfully offer?

There is no lawful way to compound KLOW today. A 503A pharmacy may compound from a bulk drug substance only if the substance has a USP or NF monograph, is a component of an FDA approved drug, or appears on the 503A bulks list. Injectable GHK-Cu meets none of those conditions: its nomination was withdrawn, it is not on the bulks list, and it was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. A mix containing it cannot be compounded lawfully.

BPC-157, TB-500, and KPV were each recommended for the 503A bulks list at the July 2026 meeting. That recommendation is advisory until FDA publishes a final rule, and a rule for those three would not cover GHK-Cu.

Advertised KLOW prices come from research-chemical sellers and clinics and are not a lawful price. Topical GHK-Cu cosmetics, sold without drug claims, are the only lawfully sold form of any KLOW ingredient. [9] [10] [11]

• GHK-Cu cost by channel
• BPC-157 cost by channel
• TB-500 (thymosin beta-4) cost by channel
• KPV cost by channel
• Rules by state
• Verified provider directory

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make KLOW lawful. GHK-Cu is not FDA approved and not on the 503A bulks list, so no pharmacy has a lawful basis to compound the mix. [10] [16]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [16] [17] [18] [19] [20]

What changes for you

• No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [20]
• Identity, purity, sterility, and dose accuracy can vary from batch to batch. [16]
• Insurance rarely covers it, so you usually pay cash.
• For tested athletes, KLOW contains at least one ingredient that is prohibited at all times on the WADA list. [12]

What to check

These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:

• A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [20]
• A real evaluation by a licensed prescriber, not just an online form.
• A certificate of analysis for the specific batch.

Compare the ingredients

• BPC-157 vs GHK-Cu
• BPC-157 vs KPV
• BPC-157 vs TB-500
• TB-500 vs GHK-Cu
• BPC-157 vs ARA-290 (cibinetide)
• KPV vs LL-37
• Thymosin alpha-1 vs TB-500 (thymosin beta-4)

Blends that share an ingredient

• GLOW: GLOW is a gray-market mix of GHK-Cu, BPC-157, and TB-500 sold for skin and healing. No study has tested it, and injectable GHK-Cu has no lawful path.
• Wolverine stack: The Wolverine stack pairs BPC-157 and TB-500 for injury recovery. No study has tested the pair, and both await an FDA final rule after the July 2026 vote.

Frequently asked questions

From the blog

• Klow vs Glow peptide: what KPV adds and what is known

  Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.

• Topical vs injectable GHK-Cu: what the evidence shows

  Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared.

• What is peptide therapy? What clinics sell, what is legal, and what works

  Peptide therapy means three different things: FDA-approved drugs, compounded prescriptions, and research-only products. Here is how to tell them apart, what the evidence shows, and what it costs.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.